Your browser doesn't support javascript.
loading
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19
Wei, Fengtao; Kong, Dexiao; Li, Tao; Li, Ai; Tan, Yi; Fang, Jinfeng; Zhuang, Xianghua; Lai, Chao; Xu, Weihua; Dong, Hong; Ma, Chengen; Hong, Ke; Cui, Yuqin; Tang, Shengbin; Yu, Fenggang; Zheng, Chengyun.
  • Wei, Fengtao; Shandong University. Department of Cardiology, the Second Hospital, Cheeloo College of Medicine. CN
  • Kong, Dexiao; Shandong University. Department of Hematology, the Second Hospital, Cheeloo College of Medicine. CN
  • Li, Tao; Shandong University. Department of Infectious Disease and Hepatology, the Second Hospital, Cheeloo College of Medicine. CN
  • Li, Ai; Shandong University. Department of Hematology, the Second Hospital, Cheeloo College of Medicine. CN
  • Tan, Yi; Shandong Qilu Cell Therapy Engineering Tecnology Co. Ltd. Jinan. CN
  • Fang, Jinfeng; Shandong University. Department of Hematology, the Second Hospital, Cheeloo College of Medicine. CN
  • Zhuang, Xianghua; Shandong University. Department of Endocrinology, the Second Hospital, Cheeloo College of Medicine. CN
  • Lai, Chao; Shandong University. Department of Neurology, the Second Hospital, Cheeloo College of Medicine. CN
  • Xu, Weihua; Shandong University. Department of Gastroenterology, the Second Hospital, Cheeloo College of Medicine. CN
  • Dong, Hong; Shandong University. Nursing Department, the Second Hospital, Cheeloo College of Medicine. CN
  • Ma, Chengen; Shandong University. Department of Critical Care Medicine, the Second Hospital, Cheeloo College of Medicine. CN
  • Hong, Ke; Yinfeng Gene Technology Co. Ltd. Jinan. CN
  • Cui, Yuqin; Shandong Yinfeng Institute of Life Science. Jinan. CN
  • Tang, Shengbin; Hunan Sheng Bao Biological Technology Co. Ltd. GaoXin District. CN
  • Yu, Fenggang; Shandong Yinfeng Institute of Life Science. Jinan. CN
  • Zheng, Chengyun; Shandong University. Department of Hematology, the Second Hospital, Cheeloo College of Medicine. CN
Clinics ; 76: e2604, 2021. tab, graf
Article in English | LILACS | ID: biblio-1249585
ABSTRACT

OBJECTIVES:

The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19.

METHODS:

Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events.

RESULTS:

The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group.

CONCLUSION:

Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells Type of study: Controlled clinical trial Limits: Humans Language: English Journal: Clinics Journal subject: Medicine Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Hunan Sheng Bao Biological Technology Co. Ltd/CN / Shandong Qilu Cell Therapy Engineering Tecnology Co. Ltd/CN / Shandong University/CN / Shandong Yinfeng Institute of Life Science/CN / Yinfeng Gene Technology Co. Ltd/CN

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells Type of study: Controlled clinical trial Limits: Humans Language: English Journal: Clinics Journal subject: Medicine Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Hunan Sheng Bao Biological Technology Co. Ltd/CN / Shandong Qilu Cell Therapy Engineering Tecnology Co. Ltd/CN / Shandong University/CN / Shandong Yinfeng Institute of Life Science/CN / Yinfeng Gene Technology Co. Ltd/CN